Cadila Pharmaceuticals Unveils Ciledge Trio: A Revolutionary Triple-Action Therapy for Enhanced Blood Pressure Control
Cadila Pharmaceuticals has launched Ciledge Trio, a groundbreaking fixed-dose combination therapy that combines Cilnidipine, Telmisartan, and Metoprolol to provide sustained blood pressure control and improved cardioprotection for hypertensive patients. Dr. Rajiv I. Modi, CMD, emphasizes the therapy's efficacy, safety, and long-term cardiovascular benefits, marking a significant advancement in hypertension management.
In a significant advancement for hypertension management, Cadila Pharmaceuticals has officially launched Ciledge Trio, a cutting-edge fixed-dose combination therapy aimed at delivering sustained blood pressure (BP) control while enhancing patient tolerability and adherence. This innovative treatment is particularly beneficial for hypertensive patients with underlying heart conditions, addressing a critical gap in cardiovascular care.
Ciledge Trio uniquely combines three well-established antihypertensive agents: Cilnidipine, a calcium channel blocker (CCB); Telmisartan, an angiotensin receptor blocker (ARB); and Metoprolol, a β1-selective blocker. Each component works synergistically through complementary mechanisms to achieve stronger and more consistent BP reduction. Clinical studies have demonstrated that combination therapy is a superior approach for sustained control and enhanced cardioprotection, especially in patients with co-existing cardiac conditions or a history of myocardial infarction.
One of the standout features of Cilnidipine is its significantly lower incidence of pedal edema—up to ten-fold less compared to conventional CCBs. When combined with Telmisartan, it not only offers effective and sustained BP control but also boasts a favorable safety profile, making it an excellent choice for patients with diabetes and chronic kidney disease. The addition of Metoprolol further enhances heart-rate control and overall cardiovascular protection, making Ciledge Trio a comprehensive solution for managing hypertension.
By integrating all three agents into a single-pill formulation, Ciledge Trio effectively reduces the pill burden that often hampers treatment adherence. This is crucial, as improved adherence is linked to better long-term clinical outcomes. The therapy is particularly targeted at hypertensive patients with underlying cardiac issues such as angina, myocardial infarction, and heart failure, where consistent BP control and cardioprotection are paramount.
The launch of Ciledge Trio is backed by Cadila’s proprietary Tri-tab technology, an innovative triple-layered tablet platform that surpasses conventional bi-layered designs. This advanced system allows for the rational combination of three active ingredients in a single, high-purity delivery form, ensuring enhanced stability, reduced drug-drug incompatibility, and consistent plasma drug levels. The precise three-layer structure also optimizes the absorption of all three components, providing a therapeutic advantage over standard film-coated tablets.
Dr. Rajiv I. Modi, CMD of Cadila Pharmaceuticals, stated, "Cadila Pharmaceuticals reinforces its commitment to addressing unmet needs in hypertension management. This guideline-driven combination is designed to deliver efficacy, safety, and long-term cardiovascular protection—key elements for improving patient outcomes in real-world clinical practice."
With the introduction of Ciledge Trio, Cadila Pharmaceuticals not only strengthens its cardiovascular portfolio but also plays a pivotal role in enhancing hypertension control, contributing to broader efforts aimed at reducing India’s long-term cardiovascular disease burden. This launch marks a promising step forward in the quest for better health outcomes for millions of patients battling hypertension.